Drug Profile
SN 522
Alternative Names: SN522Latest Information Update: 26 Sep 2011
Price :
$50
*
At a glance
- Originator Sention
- Developer Cognition Pharmaceuticals
- Class Antidementias
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cognition disorders
Most Recent Events
- 19 Jan 2005 Phase-I clinical trials in Cognition disorders in United Kingdom (unspecified route)
- 12 Feb 2002 Preclinical trials in Cognition disorders in United Kingdom (unspecified route)